

DOI: 10.53555/ks.v12i4.3839

Clinico-Pathological Significance of Cancer Cell Stem Marker Nestin Immunohistochemical Expression in Pediatric and Adult Brain Glioma

Sabeen Nasir^{1*}, Asif Ali², Shabnam Wazir³, Mehwish Nowshad⁴, Nazli Gul⁵, Summaya Zafar Jalal⁶, Ishaq Khan⁷

¹*Professor, Department of Pathology Jinnah Medical College, Peshawar, Khyber Medical University, Peshawar, Pakistan

²Professor, Department of Pathology, Institute of Pathology and Diagnostic Medicine, Khyber Medical University, Peshawar, Pakistan

³Lecturer Department of Anatomy, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan

⁴Lecturer Department of Pathology, Institute of Pathology and Diagnostic Medicine, Khyber Medical University, Peshawar, Pakistan

⁵Assistant Professor, Department of Pathology, Bannu Medical College, Khyber Medical University, Peshawar, Pakistan

⁶Senior Lecturer, Department of Anatomy Jinnah Medical College, Peshawar, Khyber Medical University, Peshawar, Pakistan

⁷Assistant Professor, Department of Cancer Genetic, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan

***Corresponding author:** Dr. Sabeen Nasir

*Professor, Department of Pathology Jinnah Medical College, Peshawar, Khyber Medical University, Peshawar, Pakistan. E-mail: sabeenpmc@gmail.com

Abstract

Background: Gliomas, the most common CNS tumors, exhibit significant clinical and molecular differences between pediatric and adult populations. Nestin, a neural progenitor marker associated with tumor invasiveness and stem-like properties, has been studied in adult gliomas but less so in pediatric cases. Investigating Nestin's immunohistochemical expression in both groups may reveal age-specific patterns and provide insights into glioma biology and potential therapeutic targets.

Objective: In the present study, we aimed to determine clinico-pathological significance of nestin immunohistochemical expression in pediatric and adult gliomas

Methods: Expression of Nestin in cancer cells was immunohistochemically studied in 128 patients and its association with clinico-pathological features in pediatric and adult gliomas was evaluated.

Results: Among 128 glioma cases (18 pediatric, 110 adult), Nestin expression was significantly higher in adults. Over 80% Nestin-positive cells were observed in 43% of adult tumors versus 12% in pediatric cases. Adult gliomas also showed greater staining intensity and IRS, with moderate-to-strong expression predominant. ($P = 0.05$).

Conclusion: Nestin expression was markedly elevated in adult gliomas, indicating its association with tumor aggressiveness and potential utility as a cancer stem cell marker in age-specific glioma profiling.

Key words: Nestin, Glioma, Neoplastic Stem Cells, Immunohistochemistry, Brain Neoplasms

Introduction

The most frequent primary tumors of the central nervous system (CNS) are gliomas¹, which vary greatly in their histological and molecular features in both adult and paediatric populations².

Due to differences in their embryonic origins and tumor microenvironment³, these tumors represent a broad spectrum of malignancies that exhibit distinct biological behaviors and clinical presentations⁴. Nestin, a class VI intermediate filament protein, has drawn interest among the biomarkers linked to gliomas because of its function in neurogenesis and expression in undifferentiated brain progenitor cells⁵.

The expression of nestin, which is mostly found in high-grade gliomas⁶, has been linked to the hallmarks of glioma biology⁷, including tumor invasiveness, proliferation, and stem-like features. Several CNS cancers, including gliomas, have been shown to express it immunohistochemically⁸ higher levels are frequently associated with aggressive tumor characteristics⁹. However, little is known about how it manifests in pediatric gliomas in contrast to adult gliomas¹⁰. Analyzing Nestin expression may shed light on the pathobiology of gliomas and their developmental variations¹¹, given the different molecular landscapes of gliomas in these age groups.

The objective of this study is to examine the localization, intensity, and distribution of Nestin's immunohistochemistry expression in tumor tissues in both pediatric and adult gliomas¹². We aim to improve our knowledge of Nestin's function in the genesis and evolution of gliomas by describing the expression patterns of the protein in different age group¹³. These results could contribute to the larger area of neuro-oncology by laying the groundwork for future studies into age-specific glioma biomarkers and treatment targets¹⁴.

Objective

In the present study, we aimed to determine clinico-pathological significance of nestin expression in pediatric and adult gliomas.

Materials and methods

Ethics statements

The Institutional Ethical Committee IPDM KMU (KMU/IPMD/IEC/2022/8) approved the current study, which complied with the Declaration of Helsinki procedure.

Patients and tissue specimens

This prospective cohort study comprised 128 glioma patients who were admitted to Prime Teaching Hospital between January 2023 and September 2024. Patients who underwent radiation therapy or chemotherapy prior to surgery were not included. The World Health Organization's (WHO) classification of brain tumors served as the basis for the histological diagnosis. The structured proforma contained all of the individual data.

Inclusion Criteria:

1. De novo patients of all age groups with gliomas diagnosed on biopsy in the Pakistani population of Khyber Pakhtunkhwa.
2. All biopsy specimens classified as grade I-IV gliomas based on H&E staining

Exclusion Criteria:

1. Brain tumor patients diagnosed other than glioma on biopsy examination
2. All biopsy specimens having any kind of artifacts
3. Patients who received preoperative chemotherapy and/or radiotherapy were excluded

Optimization of Antibodies

Before all of the glioma samples were finally immunohistochemically stained with Nestin antibody, the optimal staining signal—that is, a clear stain with the highest intensity and the least amount of background staining—was obtained by adjusting the dilution and antigen retrieval times. The sections were left at room temperature for one hour to react with a 1000-times-diluted anti-Nestin antibody (clone 10C2, Vitro China). To recover the antigen, the sections were autoclaved for 10 minutes at 121°C in 0.01 mol/L citrate buffer (pH 6.0) with 0.1% Tween 20.

Evaluation of immunohistochemical staining

Microscopic analysis of the IHC slides revealed that the tumor cells expressed nestin cytoplasmic immunostaining, which was deemed to be positive..

The Immuno Reactive Score (IRS) is a semi-quantitative evaluation that is calculated by multiplying the staining intensity by the percentage of tumor cells that have been positively indicated. The percentage of positive cells is rated as: [0] no positive cells; [1] <10% positive cells; [2] 10-50% positive cells; [3] 51-80% positive cells; and [4] >80% positive cells. Staining intensity is scored as [0] negative, [1] mild, [2] moderate [3] intense. The percentage of positive cells score is multiplied by the staining intensity score to calculate an IRS value between 0-12 which is interpreted as 0-1= negative, 2-3= weak staining, 4-8= moderate staining, and 9-12 = strong staining.

Statistical analysis

SPSS version 23.0 software was used for all statistical analyses (SPSS Inc., Chicago, Illinois). Either Fisher's exact test or Pearson's χ^2 test, if applicable, were used to evaluate the associations between nestin expression and clinicopathological characteristics. Differential significance was defined as a P-value of less than 0.05. P-values that are presented are all two-sided.

Results

Patient characteristics

There was a total of 128 cases included in this study. The age range was from 3-75 years with a mean age of 33.6 years (S.D $\pm$ 17.06 years). Demographic details of all patient are given in Table 1 to 4.

Table 1: Frequency of glioma patient according to age groups.

	Frequency	Percent
Pediatric	18	14.06
Adult	110	85.04
Total	128	100

Table 2: Frequency of glioma patient according to gender:

Gender	Pediatric	Adult	Total	P value
Male	14	71	85	0.271
Female	4	39	43	
	18	110	128	


Table 3: Frequency of glioma patient according to site:

Site	Pediatric	Adult	Total	P value
Supratentorial	12	87	99	0.243
Infratentorial	6	23	29	
	18	110	128	


Table 4: Frequency of glioma patient according to laterality:

Laterality	Pediatric	Adult	Total	P value
Left	8	49	57	0.491
midline	3	9	12	
Right	7	52	59	
	18	110	128	

The analysis of Nestin-positive cells revealed notable differences between pediatric and adult gliomas. Adult glioma cases predominantly showed a higher percentage of Nestin-positive cells, with 43% of cases demonstrating >80% positivity. In contrast, only 12% of pediatric cases reached this expression level. The lower percentage ranges (<10% and 10–50%) were almost exclusively observed in adults, indicating more variable expression in this group shown in figure 1. These findings suggest that adult gliomas tend to exhibit a higher degree of Nestin-positive cell proliferation compared to pediatric gliomas.

**Figure 1: Expression of nestin percent positive cells in pediatric and adult glioma patients**

Staining intensity further emphasized this disparity. A majority of adult gliomas demonstrated moderate (57%) to strong (33%) Nestin expression. In pediatric gliomas, moderate intensity was the most common (11%), while strong intensity was infrequent shown in figure 2. This pattern supports a more robust activation of Nestin-related pathways in adult tumors, which may reflect their more aggressive or differentiated phenotypes.

**Figure 2: Expression of nestin Intensity in pediatric and adult glioma patients**

The IRS distribution again showed a trend of elevated Nestin expression in adults. Moderate staining was the dominant category in adults (58%), followed by mild (28%) and strong (21%) staining. In pediatric gliomas, the majority fell within the moderate staining range (16%), with minimal cases showing strong staining shown in figure 3. These results align with intensity data, reinforcing the observation that adult gliomas exhibit higher overall Nestin expression.




Figure 3: Expression of nestin IRS in pediatric and adult glioma patients

Discussion

Neural stem cells and undifferentiated states in a variety of malignancies, including gliomas have long been linked to the class VI intermediate filament protein nestin¹⁵, examining its immunohistochemistry expression in both pediatric and adult gliomas with an eye toward possible associations with pathological and clinical factors was the goal of this investigation¹⁶. According to our research, there was no statistically significant correlation between Nestin expression in either group and either gender, tumor laterality, or tumor site. This is in line with earlier research, like that conducted by Ben G. McGahan et al¹⁷ and Strojnik et al¹⁸. Which found that nestin expression is more closely associated with the biological features of gliomas than with tumor location or patient demographics. These findings highlight Nestin's function as a biomarker that is unaffected by outside clinical variables and highlights its connection to intrinsic tumor behavior¹⁹.

The statistically significant correlation between the immunoreactivity score (IRS) and the proportion of Nestin-positive cells in both pediatric and adult gliomas was a noteworthy finding of our study. Given that tumors with a higher proportion of Nestin-positive cells were linked to higher IRS values, this study emphasizes the biological significance of Nestin expression levels. Similar patterns have been shown in earlier research, such as that conducted by Strojnik et al¹⁸, wherein Nestin expression was linked to higher tumor grades, enhanced proliferative potential, and a phenotype resembling stem cells²⁰. This implies that underlying tumor aggressiveness and plasticity are reflected in the positive connection between IRS and Nestin-positive cells²¹.

Our results are in line with research indicating that, despite the fact that pediatric gliomas have different genetic and molecular profiles than adult gliomas, Nestin's function as a glioma stemness marker is constant²². According to research by Sottoriva et al., gliomas in children and adults share stem-like tumor niches that are marked by strong Nestin expression²³. This lends credence to the idea that Nestin could function as a universal indicator of glioma biology at any age. This correlation's constancy across age groups highlights Nestin's potential use as a biomarker for glioma characterization in a range of clinical settings.

Furthermore, the strong correlation between IRS and Nestin-positive cells might be due to Nestin's role in angiogenesis, hypoxia adaption, and invasive potential—processes that are essential to the development of gliomas²⁴. Nestin expression is frequently elevated in hypoxic tumor areas, where it promotes invasion and survival, according to a prior study by Mertens et al.²⁵ given that these regions most likely reflect areas of enhanced malignancy and adaptability to unfavorable microenvironmental settings, this could help to explain the raised IRS in tumors with a large percentage of Nestin-positive cells. These results provide a mechanistic relationship between high Nestin expression and tumor aggressiveness and are consistent with research investigating the role of Nestin in tumor vascularization and its association with invasive characteristics²⁶.

Although there have been prior reports of gender variations in glioma incidence²⁷, it is interesting to note that the lack of relationships with clinicopathological characteristics like laterality and gender highlights the intrinsic, tumor-specific nature of Nestin expression. Although demographic and anatomical factors affect tumor incidence and appearance⁽²⁸⁾, they do not seem to have an impact on Nestin expression patterns, according to glioma studies like those from the Glioma Atlas Project²⁹. The notion that Nestin's function is based on the cellular and molecular dynamics of the tumor rather than the patient's outward features is supported by this observation¹⁷.

Conclusion:

Our results, taken together, contribute to the increasing amount of data showing that Nestin is a significant indicator of glioma aggressiveness, independent of patient characteristics. Nestin-positive cells' significant correlation with IRS validates its use as a marker of tumor growth and adaptability.

Recommendations

The molecular processes controlling Nestin expression and its functional significance in glioma subtypes should be further explored in future studies. Furthermore, research on therapeutic techniques that target Nestin-positive tumor cell types may offer fresh methods for treating gliomas in both adult and pediatric age groups.

Limitations

Small biopsy specimens and difficulty performing brain parenchymal lesion biopsies were factors in the diagnostic difficulties.

References:

1. The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis | European Journal of Medical Research [Internet]. [cited 2024 Nov 28]. Available from: <https://link.springer.com/article/10.1186/s40001-023-01011-y>
2. Frontiers | Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline [Internet]. [cited 2024 Nov 28]. Available from: <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.960509/full>
3. Lazow MA, Palmer JD, Fouladi M, Salloum R. Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management. *Neurotherapeutics*. 2022 Oct 1;19(6):1733–51.
4. Heo YJ, Hwa C, Lee GH, Park JM, An JY. Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes. *Mol Cells*. 2021 Jul 1;44(7):433–43.
5. Intricate relationship between cancer stemness, metastasis, and drug resistance - Dakal - 2024 - MedComm - Wiley Online Library [Internet]. [cited 2024 Nov 28]. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/mco.2710>
6. An S, Song IH, Woo CG. Diagnostic Value of Nestin Expression in Adult Gliomas. *Int J Surg Pathol*. 2023 Sep 1;31(6):1014–20.
7. The Hallmarks of Glioblastoma: Heterogeneity, Intercellular Crosstalk and Molecular Signature of Invasiveness and Progression [Internet]. [cited 2024 Nov 28]. Available from: <https://www.mdpi.com/2227-9059/10/4/806>
8. Cancer Stem Cells in Tumours of the Central Nervous System in Children: A Comprehensive Review [Internet]. [cited 2024 Nov 28]. Available from: <https://www.mdpi.com/2072-6694/15/12/3154>
9. Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate | Scientific Reports [Internet]. [cited 2024 Nov 28]. Available from: <https://www.nature.com/articles/s41598-020-58995-4>
10. The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2—Summary of Imaging Findings on Pediatric-Type Diffuse High-Grade Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Circumscribed Astrocytic Gliomas - Park - 2023 - Journal of Magnetic Resonance Imaging - Wiley Online Library [Internet]. [cited 2024 Nov 28]. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/jmri.28740>
11. Frontiers | Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications [Internet]. [cited 2024 Nov 28]. Available from: <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.703764/full>
12. Significance of Nestin and CD133 as cancer stem cell markers in diffuse glioma and association with p53 expression and IDH status - PMC [Internet]. [cited 2024 Nov 28]. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11301415/>
13. Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives [Internet]. [cited 2024 Nov 28]. Available from: <https://www.mdpi.com/2072-6694/14/9/2296>
14. Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research [Internet]. [cited 2024 Nov 28]. Available from: <https://www.mdpi.com/1422-0067/24/1/348>
15. Neural is Fundamental: Neural Stemness as the Ground State of Cell Tumorigenicity and Differentiation Potential | Stem Cell Reviews and Reports [Internet]. [cited 2024 Nov 28]. Available from: <https://link.springer.com/article/10.1007/s12015-021-10275-y>
16. Clinico-Radio-Histo-Molecular and Neurocognitive Characteristics of Diffuse Gliomas in Adolescent and Young Adults: A Comprehensive Review | Oncology | Karger Publishers [Internet]. [cited 2024 Nov 28]. Available from: <https://karger.com/ocl/article-abstract/101/4/240/832432/Clinico-Radio-Histo-Molecular-and-Neurocognitive?redirectedFrom=fulltext>
17. Full article: KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker [Internet]. [cited 2024 Nov 29]. Available from: <https://www.tandfonline.com/doi/full/10.1080/10408363.2024.2309933>
18. Strojnik T, Røslund GV, Sakariassen PO, Kavalari R, Lah T. Neural stem cell markers, nestin and musashi proteins, in the progression of human glioma: correlation of nestin with prognosis of patient survival. *Surg Neurol*. 2007 Aug 1;68(2):133–43.
19. Validating advanced MRI features as surrogate biomarkers of the molecular subgroups of glioblastoma by exploiting patient-specific cancer stem cell (CSC)-based animal models. [Internet]. [cited 2024 Nov 28]. Available from: <https://iris.univr.it/handle/20.500.11768/136637>

20. Nestin Expression as a Diagnostic and Prognostic Marker in Colorectal Cancer and Other Tumors - Anna Szymańska-Chabowska, Filip Świątkowski, Beata Jankowska-Polańska, Grzegorz Mazur, Mariusz Chabowski, 2021 [Internet]. [cited 2024 Nov 28]. Available from: <https://journals.sagepub.com/doi/full/10.1177/11795549211038256>
21. Hypothetical involvement of stress hormones-induced reprogramming of adult stem/progenitor cells in tumorigenesis [Internet]. [cited 2024 Nov 28]. Available from: <https://www.explorationpub.com/Journals/eemd/Article/101412>
22. Tumor cell network integration in glioma represents a stemness feature | *Neuro-Oncology* | Oxford Academic [Internet]. [cited 2024 Nov 28]. Available from: <https://academic.oup.com/neuro-oncology/article/23/5/757/6035154>
23. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. *Proc Natl Acad Sci U S A*. 2013 Mar 5;110(10):4009–14.
24. Boyd NH, Tran AN, Bernstock JD, Etminan T, Jones AB, Gillespie GY, et al. Glioma stem cells and their roles within the hypoxic tumor microenvironment. *Theranostics*. 2021 Jan 1;11(2):665–83.
25. Hypoxia and oxygenation induce a metabolic switch between pentose phosphate pathway and glycolysis in glioma stem-like cells | *Acta Neuropathologica* [Internet]. [cited 2024 Nov 29]. Available from: <https://link.springer.com/article/10.1007/s00401-013-1173-y>
26. Chaudhary A, Raza SS, Haque R. Transcriptional factors targeting in cancer stem cells for tumor modulation. *Semin Cancer Biol*. 2023 Jan 1;88:123–37.
27. Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas | *Neuro-Oncology* | Oxford Academic [Internet]. [cited 2024 Nov 29]. Available from: <https://academic.oup.com/neuro-oncology/article/24/2/302/6350590>
28. Hollhumer R, Williams S, Michelow P. Ocular surface squamous neoplasia: Population demographics, pathogenesis and risk factors. *Afr Vis Eye Health* [Internet]. 2020 Jun 23 [cited 2024 Nov 29];79(1). Available from: <https://avehjournal.org/index.php/aveh/article/view/553>
29. Regional healthy brain activity, glioma occurrence and symptomatology | *Brain* | Oxford Academic [Internet]. [cited 2024 Nov 29]. Available from: <https://academic.oup.com/brain/article/145/10/3654/6709376>